Treprostinil Technosphere News Today : Breaking News, Live Updates & Top Stories | Vimarsana

United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution Tyvaso DPI NDA filing anticipated in April 2021 with priority review News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 /PRNewswire/ -- United Therapeutics Corpora...

United Therapeutics Announces Agreement To Acquire Priority Review Voucher Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for ...